Survodutide vs PNC-27
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideImmune Support
PNC-27- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- Half-Life
- ~7 days
- Not well established; estimated minutes to hours
- Admin Route
- SubQ
- Intravenous (research), Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Not established for humans; research doses vary by cell line and model
- Frequency
- Once weekly
- Not established for human use
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Stacks With
- —
- —